Plexus Corp announced that it has been selected to develop QIAGEN's next generation automated screening system for the pre-processing of human papillomavirus (HPV) DNA samples. This product provides a highly automated solution to a current manual process, through sophisticated robotic motions. QIAGEN is said to be the market leader in DNA based screening for HPV; a virus that has an established link to cervical cancer. This contract for the final development phase builds on the existing collaboration which led to the first prototypes.
"We are thrilled about our partnership with QIAGEN, as it pairs two world class companies to create an industry leading product," stated Steve Frisch, Sr Vice President, Global Engineering Services. "Plexus sees this relationship as an indication of how we can utilize our full suite of engineering capabilities, coupled with our complete product realization services, to provide mechatronic solutions for our customers developing complex medical equipment."
"Plexus' proven track record of assisting customers in bringing complex medical devices to market, coupled with its ability to quickly staff this program from its five Global Design Centers, made them an ideal partner," commented Dr Jim Godsey, Sr Vice President, North America Research & Development at QIAGEN. "Thanks to this partnership we will be able offer a unique frontend solution for our next generation high throughput screening platform, which will help QIAGEN further maintain its market leadership in the life sciences and diagnostics markets."
